Orgenesis Inc. (NASDAQ:ORGS) Q4 2022 Earnings Conference Call March 21, 2023 11:00 AM ET

Company Participants

David Waldman - Investor Relations

Vered Caplan - Chief Executive Officer

Neil Reithinger - Chief Financial Officer

Conference Call Participants

Bruce Jackson - Benchmark Company

William Jordan - TSA Investment

Steve Waite - Gilder Publishing

Operator

Greetings. Welcome to the Orgenesis 2022 Year End Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]

Please note, this conference is being recorded. I will now turn the conference over to your host, David Waldman, Investor Relations. You may begin.

David Waldman

Thank you. Good morning, everyone. And welcome to the Orgenesis year end business update conference call. On the call with us this morning are Vered Caplan, Chief Executive Officer; and Neil Reithinger, Chief Financial Officer. If you have any questions after the call, would like any additional information about the company, please contact Crescendo Communications at 212-671-1020.

This conference call contains forward-looking statements, which are made pursuant to the Safe Harbor provisions of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities and Exchange Act of 1934 as amended.

These forward-looking statements involve substantial uncertainties and risks and are based upon current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this conference call.

We caution listeners that forward-looking statements are predictions based on our current expectations about future events. These future -- these forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict.

Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to the risks and uncertainties discussed under the heading Risk Factors in Item 1A of our annual report on Form 10-K for the fiscal year ended December 31, 2022, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

I’d now like to turn the call over to Orgenesis CEO, Ms. Vered Caplan. Please go ahead, Vered.

Vered Caplan

Thank you, David, and thanks to everyone for joining us on our call today. We are advancing the rollout of our Orgenesis Mobile Processing Units and Labs, also known as OMPULs, which are fully integrated all in one bioprocessing units that can be rapidly implemented as a standardized industrial clean emautomative at the point-of-care.